
Opinion|Videos|November 1, 2024
Defining mCSPC: Diagnostic Criteria, Imaging Approaches, and Patient Identification
Key Takeaways
- mCSPC and mHSPC refer to prostate cancer with metastases that remain responsive to hormone therapy, often used interchangeably.
- Both conditions involve the presence of metastases and sensitivity to androgen deprivation therapy (ADT).
Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is defined by its sensitivity to androgen deprivation therapy, while metastatic hormone-sensitive prostate cancer (mHSPC) emphasizes the cancer’s responsiveness to hormone treatment, highlighting the nuanced differences in patient management strategies.
Advertisement
Video content above is prompted by the following:
How do you define mCSPC and mHSPC? How are they different? (
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
AI-generated profiles impersonate female urologists to market ED products online
2
John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC
3
Doublet or triplet? Urologists weighs in on mCSPC options
4
Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD
5






